SMTI vs BDX vs BAX vs HSIC

For growth investors, Sanara MedTech Inc.

(SMTI) is the stronger pick with 19. 0% revenue growth year-over-year, versus 4. 0% for Henry Schein, Inc. (HSIC). Henry Schein, Inc. (HSIC) offers the better valuation at 21. 6x trailing P/E (13. 3x forward), making it the more compelling value choice. Analysts rate Sanara MedTech Inc. (SMTI) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Henry Schein, Inc.

(HSIC) is the cheapest at 21. 6x versus Becton, Dickinson and Company at 26. 3x. On forward P/E, Baxter International Inc. is actually cheaper at 9. 2x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Becton, Dickinson and Company wins at 0. 74x versus Henry Schein, Inc. 's 4. 21x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Becton, Dickinson and Company (BDX) delivered a total return of +16.

9%, compared to -74. 3% for Baxter International Inc. (BAX). Over 10 years, the gap is even starker: SMTI returned +218. 0% versus BAX's -42. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Becton, Dickinson and Company (BDX) is the lower-risk stock at 0.

66β versus Sanara MedTech Inc. 's 1. 42β — meaning SMTI is approximately 115% more volatile than BDX relative to the S&P 500. On balance sheet safety, Becton, Dickinson and Company (BDX) carries a lower debt/equity ratio of 76% versus 8% for Sanara MedTech Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Sanara MedTech Inc.

(SMTI) is pulling ahead at 19. 0% versus 4. 0% for Henry Schein, Inc. (HSIC). On earnings-per-share growth, the picture is similar: Henry Schein, Inc. grew EPS 7. 2% year-over-year, compared to -282. 5% for Sanara MedTech Inc.. Over a 3-year CAGR, SMTI leads at 31. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Becton, Dickinson and Company (BDX) is the more profitable company, earning 7.

7% net margin versus -36. 4% for Sanara MedTech Inc. — meaning it keeps 7. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BDX leads at 11. 8% versus -2. 7% for BAX. At the gross margin level — before operating expenses — SMTI leads at 92. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Becton, Dickinson and Company (BDX) is the more undervalued stock at a PEG of 0. 74x versus Henry Schein, Inc. 's 4. 21x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Baxter International Inc. (BAX) trades at 9. 2x forward P/E versus 165. 9x for Sanara MedTech Inc. — 156. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SMTI: 67. 7% to $32. 00.

In this comparison, BAX (3.

9% yield), BDX (2. 7% yield) pay a dividend. SMTI, HSIC do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Becton, Dickinson and Company (BDX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

66), 2. 7% yield). Both have compounded well over 10 years (BDX: +80. 2%, SMTI: +218. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SMTI is a small-cap high-growth stock; BDX is a mid-cap quality compounder stock; BAX is a small-cap income-oriented stock; HSIC is a small-cap quality compounder stock. BDX, BAX pay a dividend while SMTI, HSIC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.